Screener
CG Oncology CGON Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $12,727 | $5,714 |
| Operating lease liabilities, current portion | 985 | 915 |
| Accrued expenses and other current liabilities | 33,528 | 24,207 |
| Total current liabilities | 47,240 | 30,836 |
| Long-term debt | 3,000 | 3,000 |
| Operating lease liabilities, net of current portion | 4,834 | 3,106 |
| Deferred tax liability | 307 | 307 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's accrued expenses?
- CG Oncology (CGON) reported accrued expenses of $33.53M in Q2 2026.
- How has CG Oncology's accrued expenses changed year-over-year?
- CG Oncology's accrued expenses increased by 46.0% year-over-year, from $22.97M to $33.53M.
- What is the long-term trend for CG Oncology's accrued expenses?
- Over 2 years (2023 to 2025), CG Oncology's accrued expenses has grown at a 52.3% compound annual growth rate (CAGR), from $10.44M to $24.21M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about CG Oncology's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude